CCN2 and gastric cancer: The clinical and correlation analysis of primary gastric cancer showed that miR-375 targeted the three components of the Hippo pathway, YAP1, TEAD4, and connective tissue growth factor (CTGF), to exert an anti-cancer effect [10].